Terzi Sait, Dayi Sennur Unal, Akbulut Tamer, Dağ Omer, Köse Hacer, Satiroğlu Omer, Sayar Nurten, Bilsel Tuba, Aksoy Sükrü, Yeşilçimen Kemal
Clinic of Cardiology, Dr. Siyami Ersek Thorax and Cardiovascular Surgery Center, Istanbul.
Anadolu Kardiyol Derg. 2003 Dec;3(4):313-8.
It is well known that long-term therapy with beta-blockers reduces morbidity and mortality, improves left ventricular function in patients with heart failure. However the effect of beta-blockade on exercise tolerance in patients with heart failure remains unclear. In the present study we evaluated effects of the addition of bisoprolol to standart therapy with a diuretic and an angiotensin converting enzyme (ACE) inhibitor on exercise capacity in patients with chronic heart failure.
We enrolled 52 patients (mean age 59+/-11 years) with stable, mild to moderate chronic heart failure and left ventricular ejection fraction of 40% or less receiving standart therapy with diuretic and ACE inhibitor. We randomly assigned patients to bisoprolol 1.25 mg (n=28) or control (n=24) groups. The drug progressively increased to a maximum dose of 5 mg per day. Cardiopulmonary exercise testing (CPET) was performed in all patients of the bisoprolol and control groups before and after 3 months from the beginning of the study.
We found a significant increase in exercise duration, maximal O2 uptake (pik VO2), the O2 uptake at the anaerobic threshold (VO2-AT) and O2-pulse (pik VO2/HR), and improved functional capacity (p<0.001). Bisoprolol produced significant reduction in heart rate at rest (p=0.01) and during maximal exercise (p=0.041). In the control group no significant changes were observed.
The addition of bisoprolol to the standart therapy in patients with mild to moderate heart failure is well tolerated and improves functional capacity.
众所周知,β受体阻滞剂长期治疗可降低发病率和死亡率,改善心力衰竭患者的左心室功能。然而,β受体阻滞剂对心力衰竭患者运动耐量的影响仍不清楚。在本研究中,我们评估了在使用利尿剂和血管紧张素转换酶(ACE)抑制剂的标准治疗基础上加用比索洛尔对慢性心力衰竭患者运动能力的影响。
我们纳入了52例(平均年龄59±11岁)稳定的轻至中度慢性心力衰竭患者,其左心室射血分数为40%或更低,正在接受利尿剂和ACE抑制剂的标准治疗。我们将患者随机分为比索洛尔1.25mg组(n = 28)和对照组(n = 24)。药物剂量逐渐增加至最大每日剂量5mg。在研究开始后3个月,对所有比索洛尔组和对照组患者进行心肺运动试验(CPET)。
我们发现运动持续时间、最大摄氧量(峰值VO₂)、无氧阈时的摄氧量(VO₂-AT)和氧脉搏(峰值VO₂/心率)显著增加,功能能力得到改善(p<0.001)。比索洛尔使静息心率(p = 0.01)和最大运动时心率(p = 0.041)显著降低。在对照组中未观察到显著变化。
在轻至中度心力衰竭患者的标准治疗中加用比索洛尔耐受性良好,并可改善功能能力。